CRL
Charles River Laboratories International, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$290.39
−1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.0B | 4.0B | 4.0B | 4.1B | 4.0B |
| Cost of Revenue | 2.7B | 2.8B | 2.7B | 2.6B | 2.5B |
| Gross Profit | 1.3B | 1.2B | 1.3B | 1.5B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 753.5M | 743.1M | 751.0M | 747.9M | 665.1M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 42.0M | (25.3M) | 353.5M | 137.4M | 146.6M |
| Total Operating Expenses | 795.5M | 717.7M | 1.1B | 885.3M | 811.7M |
| Cost and Expenses | 3.5B | 3.5B | 3.8B | 3.5B | 3.3B |
| Operating Income (EBIT) | 493.8M | 507.8M | 227.3M | 617.3M | 651.0M |
| Non-Operating | |||||
| Interest Income | 4.5M | 4.9M | 8.6M | 5.2M | 780.0K |
| Interest Expense | 106.3M | 107.0M | 126.3M | 136.7M | 59.3M |
| Net Interest Income | (101.8M) | (102.1M) | (117.7M) | (131.5M) | (58.5M) |
| Other Non-Op Income/Expense | (677.5M) | (607.3M) | (134.2M) | (36.0M) | (28.0M) |
| Non-Operating Income (excl Interest) | 571.2M | 500.3M | 7.9M | (100.7M) | (31.3M) |
| EBT (Pre-Tax Income) | (183.7M) | (99.5M) | 93.1M | 581.3M | 623.0M |
| Income Tax Expense | 52.6M | 42.7M | 67.8M | 100.9M | 130.4M |
| Bottom Line | |||||
| Net Income | (238.5M) | (144.3M) | 10.3M | 474.6M | 486.2M |
| Earnings from Cont. Ops | (236.3M) | (142.2M) | 25.3M | 480.4M | 492.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (238.5M) | (144.3M) | 10.3M | 474.6M | 486.2M |
| Per Share | |||||
| Basic EPS | ($4.84) | ($2.91) | $0.20 | $9.27 | $9.57 |
| Diluted EPS | ($4.85) | ($2.91) | $0.20 | $9.22 | $9.48 |
| Revenue Per Share | $82.48 | $81.01 | $78.82 | $80.61 | $78.25 |
| Shares | |||||
| Basic Shares Outstanding | 48.5M | 49.6M | 51.4M | 51.2M | 50.8M |
| Diluted Shares Outstanding | 48.5M | 49.6M | 51.6M | 51.5M | 51.3M |
| Profitability Metrics | |||||
| EBITDA | 220.5M | 410.8M | 581.1M | 1.0B | 986.1M |
| D&A | 297.9M | 403.3M | 361.7M | 314.1M | 303.9M |
| EBIT | (77.4M) | 7.5M | 219.4M | 718.0M | 682.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026